Study Title

A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Study Details

Description:

This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.

Sponsor:

Aiwu Ruth He, MD

Contacts:

Aiwu R He, MD, PhD (Principal Investigator)

rmottier@hoosiercancer.org

317-634-5842 ext 60

Government Study Link:

NCT04541173 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468